CD4+ cells recovery in HIV positive patients with severe immunosuppression at HAART initiation at Centre Medico-Social Cor-Unum, Kigali

Nyiramana Marie Merci¹, Uwimana Emerence², Nzitakera Augustin¹,², Michael Habtu¹,³, Ingabire Julie¹, Tuyishime Angelique¹, Beneyo Jessica¹, Akimana Cynthia¹, Augustin Twizerimana Penda¹,²,*

¹Mount Kenya University, College of Health Sciences, Department of Medical Laboratory Sciences, Kenya ²University of Rwanda, College of Medicine and health Sciences, Department of Biomedical Laboratory Sciences, Kigali, Rwanda, ³Institute of Tropical Medicine and Infectious Diseases, Jomo Kenyatta University of Agriculture and Technology, Nairobi, Kenya

*Corresponding author: Augustin Twizerimana Penda, Mount Kenya University, College of Health Sciences, Department of Medical Laboratory Sciences, University of Rwanda, College of Medicine and health Sciences, Department of Biomedical Laboratory Sciences, Kigali, Rwanda

Key words: HAART, CD4+ cells, viremia, severe immunosuppression, immune recovery

Received: 07/08/2016 - Accepted: 16/11/2016 - Published: 12/01/2017

Abstract

Introduction: Up to 30% of HIV infected patients who are receiving HAART do not exhibit a marked increase in the CD4+ T cell count. There is still a concern that immune recovery may not be complete once CD4+ T cells have decreased below 200 cells/µl. The objective is to assess CD4+ cell recovery in HIV+ patients with CD4 count below 200 cells/µl at HAART initiation. Methods: This was a retrospective cohort study among 110 HIV+ patients with initial CD4 count < 200 cells/µl. Baseline Age, sex, CD4 count and viral load were extracted from the patient's database. After 12 months of HAART; CD4 count was done using flow cytometry and viremia by COBAS AmpliPrep/COBAS TaqMan HIV-1 test v 2.0 technology. Results: The mean age of the respondents was 35 years; males being 57% and females were 43%. The mean CD4 count before HAART was 110.18 cells/µl whereas at 12 months of HAART; this was 305.01 cells/µl. Though some patients did not achieve a CD4 count of more than 200 cells/µl or a drop in viral load; there was a significant recovery of CD4+ cells (P value=0.000) and viremia following HAART (P value=0.001). Participants aged 18-30 years were likely to have less than 200 cells/µl CD4 count (46.4%) [OR=4.33; 95%CI: 1.29-14.59; P=0.018] than participants aged above 40 years (16.7%). Conclusion: HAART was associated with viremia suppression but many patients failed to achieve a CD4 count >200 cells/µl. HAART before severe immunosuppression is a key factor for immune restoration among HIV+ patients.
**Introduction**

Human immunodeficiency virus (HIV) is a lentivirus; a member of the retrovirus family that causes Acquired Immunodeficiency Syndrome (AIDS) [1]. Human Immunodeficiency Virus Infection/Acquired Immunodeficiency Syndrome (HIV/AIDS) is among the most serious public health challenges man has ever faced; particularly in developing countries with low per capita income [2]. Approximately 35.0 million people were living with HIV worldwide by the end of 2013 [3]. The number of people receiving HIV treatment has tripled in five years and reached 9.7 million in low- and middle-income countries in 2012, and this represents 65% of the global target of 15 million people [4].

Work undertaken by the National Institute of statistics of Rwanda (NISR), in the 2010 RDHS, indicated that in Rwanda, HIV prevalence was 3.7% and 2.2% among women and men, respectively. The city of Kigali, Capital of Rwanda had the highest prevalence (7.3%) in the country [5]. Periodic CD4 count (every three months) and viral load (every 12 months) are used for HIV+ patients biological follow up that aims at assessing the infection progression as well as response to HAART [6]. The best limit CD4 count for HAART initiation is 350 cells/µl [7]. Previous studies have showed that factors including age, specific drug regimen, and initial CD4 count influence CD4 count recovery among patients with virological suppression [8-10]. A low CD4 count before treatment is a risk factor for not achieving a CD4 count > 200 cells/µl following HAART [11] and studies have documented that the lower the CD4 count at HAART initiation; the longer and more difficult it will be to achieve a net CD4+ recovery [12]. HIV+ are said to be undergoing a severe immunosuppression when their CD4 counts are below 200 cells/µl [13].

CD4 count has been reported to be one of the best surrogate markers for monitoring the progression of HIV infection and low CD4 counts are associated with increased risk of developing AIDS or death [14]. The absolute CD4 cell counts form the basis for antiretroviral therapy initiation and monitoring among HIV-infected adults though the rate of CD4 cell change differs among patients [7]. Mortality is among the late antiretroviral treatment outcome variables that have been studied extensively, and rates of up to 30% have been reported during the first year of treatment in some sub-Saharan settings [15]. Researches have documented a fast CD4+ cell recovery among patients with baseline CD4 count ≥ 200 cells/µl compared to patients with baseline CD4 <200 cells/µl [7,16]. The present study aimed at assessing CD4+ cells recovery in HIV+ patients with severe immunosuppression (CD4 count <200 cells/µl) at HAART initiation at Centre Medico-Social Cor-Unum located in Kigali.

**Methods**

This was a retrospective cohort study that started from March 2015 to February 2016. The study aimed at looking at how CD4+ cells recover when HIV+ patients initiate HAART with a severe immunosuppression. Baseline data including demographic (age and sex), CD4 count, and viral load were collected from HIV+ patient’s database (clinical file). The inclusion criteria were HIV+ patients who had initiated HAART with a CD4 count of less than 200 cells/µl.

The study was conducted at Centre Medico-Social Cor-Unum located in Kigali; the capital city of Rwanda. This health facility is a member of public health facilities in Rwanda that host voluntary counseling and testing (VCT), antiretroviral treatment services and follow up for many HIV+ patients. In addition, the area is near the National Reference Laboratory of Rwanda where viral load was to be measured and this has facilitated easy and cheap sample transportation at 12 months of HAART. Blood samples were collected from 110 study participants who had been on HAART for 12 months. The CD4 count was done using flow cytometry (BD FACSCount™ system) while viral load was determined using COBAS AmpliPrep/COBAS TaqMan HIV-1 test v2.0 technology.

Paired and independent t test were used to compare means between baseline CD4 cell; viremia and at 12 months of HAART initiation; as well as between demographics and CD4 cell/viral load respectively. Moreover, chi square test was used to determine the association between demographics and CD4 count level. The significance level was set at P value <0.005. This study was reviewed and approved by Mount Kenya University (MKU04/DPA/16/2015/3007) and Congregations Around Richmond Involved to Assure Shelter (CARITAS)-Rwanda as Centre Medico-Social Cor-Unum operates under CARITAS in partnership with the Rwanda Ministry of Health. All the patients signed the informed consent before participation to the study.


**Results**

**Demographic characteristics of study participants**

Table 1 presents the age and sex distribution of study participants. The mean age was 35 years and about half (47.3%) of the respondents were aged between 31-40 years. More males (57%) than females (43%) participated to the study.

**CD4+ cells count at HAART initiation and at 12 months of treatment**

As shown in Table 2, the 110 HIV+ patients who participated to the present study had a mean CD4 count of 110.18 cells/µl at HAART initiation with a minimum CD4 count of 1 cell/µl and a maximum of 199 cells/µl. Following 12 months of HAART, the mean CD4 count raised to 305 cells/µl. The minimum and maximum CD4 count were 2 cells/µl and 1171 cells/µl respectively. Paired samples t test was computed to determine the mean difference (110.18 cells/μl before HAART and 305.01 cells/μl after 12 months of HAART). There was a significant recovery of CD4 positive cells following HAART among study participants (P value = 0.000).

**CD4 count stratified by sex and age**

Table 3 presents the levels of CD4+ cells based on sex and age. Before HAART initiation men had a mean CD4+ count of 109.57 cells/µl and for females the mean was 111 cells/µl. The difference was not significant (P value =0.899). Following 12 months of HAART, the mean CD4+ count among females was higher (311.81 cells/µl before HAART and 305.01 cells/µl after 12 months of HAART). There was a significant difference in viral load was significant between the two time points (P value = 0.000).

**Viral load based on sex and age**

Before HAART initiation males had a mean rank viral load 59.9 compared to 49.5 among females but this was not significant (P value= 0.090). Following HAART mean rank of drop in viral load achieved by males was 55.3 and by females 55.8 (P value= 0.766). Similarly, there was no significant difference between the age and mean rank of viral load before HAART initiation (P value= 0.918) as well as age and mean rank of viral load after 12 months of HAART initiation (P value= 0.063) (Table 5).

**CD4+ cell recovery and level of viremia following HAART with regard to a target of >200 cells/µl**

CD4 Count and viral load levels were analyzed based on whether a patient achieved a CD4 count of ≥ 200 cells/µl at 12 months of HAART initiation. Despite HAART, 29 (26.4%) of study participants were still having CD4 count below 200 cells/µl compared to 81 (73.6%) participants who had a CD4 count of more than 200 cells/µl as CD4 count. As for viral load, 106 (96.4%) patients achieved a net decrease in viremia to 20 RNA copies/ml while 4 (3.6%) had an increase in their viremia (Table 6).

**Association between demographics and CD4 count level**

Table 7 shows the relationship between demographic characteristics and CD4 count level after 12 months of HAART initiation. Respondents aged 18-30 years were significantly more likely to have less than 200 cells/µl CD4 count (46.4%) [OR=4.33; 95%CI: 1.29-14.59; P=0.018] than those respondents aged above 40 years (16.7%). However, there was no significant association (P<0.05) between sex and CD4 count level after 12 months of HAART initiation.

**Discussion**

The World Health Organization recommends a limit CD4 count of 350 cells/µl or clinical stage based decision for HAART initiation; particularly in countries where viral load cannot be easily determined [7,17] and a CD4 count of less than 200 cells/µl at
HAART initiation indicates a severe immunosuppression among HIV+ patients [18]. In the present study; CD4+ cell recovery was assessed among HIV+ patients who initiated HAART with a CD4 counts of less than 200 cells/μl. Comparison between CD4 count, viral load before HAART and after 12 months of HAART was done among HIV positive patients with severe immunosuppression.

A significant recovery of CD4 positive cells and a drop in viremia following 12 months of HAART among study participants were documented and this is in agreement with findings by [7] and a study by [6]. Low CD4 count and high viral load are indicators of HIV associated immunosuppression and this explains why HAART is initiated for people with CD4 count of less than 350 cells/μl and more particularly why HIV+ patients with CD4 count below 200 cells/μl are immediately put on HAART [19]. Though most of study participants achieved a net drop in viral load following 12 months of HAART; a number of patients did not get a drop in viremia and this can suggest a treatment failure that can be associated with factors like viral mutations, regimens or defaulting during HAART [20].

Some patients saw a decrease in their viral load after 12 months of treatment. However; this was not associated with a net recovery of CD4+ cells to reach more than 200 cells/μl; as following the 12 months of HAART considerable percentage (26.4%) of participants were still having CD4 count below 200 cells/μl compared to 73.6% of participants who achieved more than 200 cells/μl as CD4 count. This finding highlights the importance of viral load for the biological follow up of HIV+ patients both before and following HAART compared to CD4 count. Several studies have reported a poor prognosis prediction by CD4 count as it sometimes does not correlate with viral load in what is known as discordant response [21] and slowness in immune system recovery when HIV+ patients start HAART with severe immunosuppression have also been highlighted [22].

Poor immunologic response has been attributed to patient factors like age, the regimen as well as viral factors. However; this was not the case in the present study where young patients were likely to have a poor immune recovery compared to old patients [23]. The present study has again shown how important is to start HAART before a severe immunosuppression; for a better immune recovery. A difference in CD4+ cells recovery between a group of HIV+ patients with severe immunosuppression and a group with CD4 count >200 cells/μl at HAART; has also been reported at six months of HAART by [6]. During this study, there was no difference in CD4 count and viral load between males and females at both time points (P>0.005). This had also been documented by Annison & Dompreh (2013) at the Komfo Anokye Teaching Hospital, Ghana [24]. Younger participants were likely to have lower CD4 count but this was not associated with in increase in viremia and could be attributed to prognostic prediction discrepancies between viral load and CD4 count [6].

Conclusion

We conclude that immune recovery is slow among HIV+ patients who start HAART with severe immunosuppression. Early HAART intervention is necessary for achieving effective CD4+ T cell responses and optimal immunological function in HIV+ patients.

What is known about this topic
- Several researchers have focused their attention on CD4+ cells recovery among HIV+ patients following HAART in general.

What this study adds
- This study has enriched the knowledge on how CD4+ cells recover among HIV+ patients when they initiate HAART after a severe immunosuppression;
- The study has again pointed out the importance of early HAART initiation among HIV+ patients particularly in the context of Rwanda where such data were scarce;
- The present study will also raise more interests among researchers on host cellular and molecular as well as viral factors behind this poor recovery in CD4+ cells.

Competing interests

The authors declare no competing interests.

Authors’ contributions

Michael Habtu; Ingabire Julie; Tuyishime Angelique; Beneyo Jessica; Akimana Cynthia and Nzitakera Augustin contributed to acquisition of lab data, and analysis. Uwimana Emerence and Nyiramana Marie Merci conceptualized the idea for the study, participated to its
design, lab work, analysis and coordination. In addition to data analysis; Michael Habtu contributed to manuscript writing. Augustin Twizerimana Penda supervised the whole process and headed the manuscript writing. Each author has given final approval of the version to be published. All the authors have read and agreed to the final manuscript.

Acknowledgments

Authors of this article are thankful to the Ministry of Health Rwanda, Mount Kenya University/Kigali campus and to the health facility where this project was carried out; for their support including but not limited to scientific and ethical review of the proposal and cooperation during data collection.

Tables

Table 1: Demographic attributes of study participants
Table 2: CD4+ cells count before HAART initiation and at 12 months of treatment
Table 3: CD4 count based on gender and age. Mean CD4 counts among females and males and their comparison are presented
Table 4: Wilcoxon signed ranks test is used to highlight the difference in viral load between the two time points under this study
Table 5: Viral load level based on sex and age. However, there was no significant difference detected between the groups
Table 6: CD4+ cell recovery and level of viremia following HAART with regard to a target of >200 cells/μl
Table 7: Association between demographics and CD4 count level

References

1. Schaller T, Herold N. The Early Bird Catches the Worm - Can Evolution Teach us Lessons in Fighting HIV? Current HIV Research. 2016;14(3):183-210. PubMed | Google Scholar

2. Suleiman IA, Momo A. Adherence to antiretroviral therapy and its determinants among persons living with HIV/AIDS in Bayelsa state, Nigeria. Pharmacy Practice. 2016;14(1):631. PubMed | Google Scholar

3. Teshome W, Tefera A. Detection of immunological treatment failure among HIV infected patients in Ethiopia? a retrospective cohort study. BMC Immunology. 2015 Sep 16;16:55. PubMed | Google Scholar

4. Hirnschall G, Harries AD, Easterbrook PJ, Doherty MC, Ball A. The next generation of the World Health Organization’s global antiretroviral guidance. Journal of the International AIDS Society. 2013 Jun 30;16:18757. PubMed | Google Scholar

5. National Institute of Statistics of Rwanda. DHS report retrieved from http://www.measuredhs.com/pubs/pdf/PR7/PR7.pdf. 2010. Google Scholar

6. Twizerimana AP, Mwatha J, Musabyimana JP, Kayigi E, Harelimana JD, Karanja SM, Mutesa L. Immunological profiles in HIV positive patients following HAART initiation in Kigali, Rwanda. East African Medical Journal. 2014;91(8):261-6. PubMed | Google Scholar

7. Nanzigu S, Kiguba R, Kabanda J, Mukonzo JK, Waako P, Kityo C, Makumbi F. Poor immunological recovery among severely immunosuppressed antiretroviral therapy-nave Ugandans. HIV/AIDS - Research and Palliative Care. 2013;5:309-319. PubMed | Google Scholar

8. Mocroft A, Phillips AN, Ledergerber B, Katlama C, Chiesi A, Goebel FD et al. Relationship between antiretrovirals used as part of a cART regimen and CD4 cell count increases in patients with suppressed viremia. AIDS. 2006 May 12;20(8):1141-50. PubMed | Google Scholar

9. Althoff KN, Justice AC, Gange SJ, Deeks SG, Saag MS, Silverberg MJ, et al. Virologic and immunologic response to HAART, by age and regimen class. AIDS. 2010 Oct 23;24(16):2469-79. PubMed | Google Scholar

10. Smit M, Smit C, Geerlings S, Gras L, Brinkman K, Hallett TB et al. Changes in first-line cART regimens and short-term clinical outcome between 1996 and 2010 in The Netherlands. PLoS One. 2013 Sep 30;8(9):e76071. PubMed | Google Scholar
11. Engsig FN, Zangerle R, Katsarou O, Dabis F, Reiss P, Gill J et al. Long-term mortality in HIV-positive individuals virally suppressed for >3 years with incomplete CD4 recovery. Clin Infect Dis. 2014 May;58(9):1312-21. PubMed | Google Scholar

12. Lodi S et al. Comparative effectiveness of immediate antiretroviral therapy versus CD4-based initiation in HIV-positive individuals in high-income countries: observational cohort study. The Lancet HIV. 2015;2(8): 335-43. PubMed | Google Scholar

13. WHO. Interim WHO clinical staging of HIV/AIDS and HIV/AIDS case definitions for surveillance available at http://www.who.int/hiv/pub/guidelines/clinicalstaging.pdf. 2005. Retrieved on 26.07.2016. PubMed | Google Scholar

14. Ingole NA, Kukreja SM, Mehta PR. Role of HIV-1 viral load in initiating antiretroviral therapy. World Journal of AIDS. 2011; 01(04):149-154. PubMed | Google Scholar

15. Lahuerta MU, Hoffman S, Elul B, Kulkarni SG, Wu Y, Nash D. The problem of late ART initiation in Sub-Saharan Africa: a transient aspect of scale-up or a long-term phenomenon?. Journal of Health Care for the Poor and Underserved. 2013;24(1):359-83. PubMed | Google Scholar

16. Moore RD, Keruly JC. CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression. Clinical infectious diseases. 2007;44(3):441-446. PubMed | Google Scholar

17. Olubajo B, Mitchell F K, Ogunmoroti O. A comparative systematic review of the optimal CD4 cell count threshold for HIV treatment initiation. Interdisciplinary Perspectives on Infectious Diseases. 2014; 7–12. Google Scholar

18. Boniphace I, Omari M, Susan Fred R, Ferdinand M, Marcel T. HIV/AIDS clinical manifestations and their Implication for patient clinical staging in resource limited settings in Tanzania. The Open AIDS Journal. 2011;5:9-16. PubMed | Google Scholar

19. Gatell JM. When and why to start antiretroviral therapy? The Journal of Antimicrobial Chemotherapy. 2010;65(3):38-5. PubMed | Google Scholar

20. Kandathil AJ, Kannangai R, Verghese VP, Pulimood SA, Rupali P, Sridharan G, Abraham OC. Drug resistant mutations detected by genotypic drug resistance testing in patients failing therapy in clade C HIV-1 infected individuals from India. Indian Journal of Medical Microbiology. 2009;27(3):231-6. PubMed | Google Scholar

21. Prabhakar B, Banu A, Pavithra HB, Chandrashekhara P, Sasthri S. Immunological failure despite virological suppression in HIV seropositive individuals on antiretroviral therapy. Indian Journal of Sexually Transmitted Diseases. 2011;32(2):94-8. PubMed | Google Scholar

22. Geng EH, Deeks SG. CD4+ T cell recovery with antiretroviral therapy: more than the sum of the parts. Clinical Infectious Diseases? An Official Publication of the Infectious Diseases Society of America. 2009;48(3):362-4. PubMed | Google Scholar

23. Nasi M, Pinti M, Bugarini R, Troiano L, Lugli E, Bellodi C, Cossarizza A. Genetic polymorphisms of Fas (CD95) and Fas ligand (CD178) influence the rise in CD4+ T cell count after antiretroviral therapy in drug-naïve HIV-positive patients. Immunogenetics. 2005;57(9):628-35. PubMed | Google Scholar

24. Annison L, Dompreh A. The immunological response of HIV-positive patients initiating HAART at the Komfo Anokye Teaching Hospital. Ghana medical journal. 2013;47(4):164-70. PubMed | Google Scholar
### Table 1: Demographic attributes of study participants

| Variable       | n=110 | %   |
|----------------|-------|-----|
| **Age in years** |       |     |
| 18-30          | 28    | 25.5|
| 31-40          | 52    | 47.3|
| > 40           | 30    | 27.3|
| **Mean age (±SD)** = 35.2(±8.5) |       |     |
| **Sex**        |       |     |
| Female         | 47    | 42.7|
| Male           | 63    | 57.3|

### Table 2: CD4+ cells count before HAART initiation and at 12 months of treatment

|                          | Before HAART | At 12 months of HAART | Paired t-test |
|--------------------------|--------------|------------------------|---------------|
| Number of Patients       | 110          | 110                    | 0.000         |
| Mean                     | 110.18       | 305.01                 |               |
| Minimum CD4 count        | 1            | 2                      |               |
| Maximum CD4 count        | 199          | 1171                   |               |
Table 3: CD4 count based on gender and age. Mean CD4 counts among females and males and their comparison are presented

| Variables                                      | N  | Mean | Std. Deviation | Independent t test/ANOVA test |
|------------------------------------------------|----|------|----------------|-------------------------------|
| CD4+ cells Count before HAART initiation based on sex |    |      |                |                               |
| Male                                           | 63 | 109.57 | 56.76          | 0.899                         |
| Female                                         | 47 | 111   | 60.16          |                               |
| CD4 count at 12 months of treatment based on sex |    |      |                |                               |
| Male                                           | 63 | 299.94 | 152.98         | 0.726                         |
| Female                                         | 47 | 311.81 | 201.75         |                               |
| CD4+ cells Count before HAART initiation based on age |    |      |                |                               |
| 18-30 years                                    | 28 | 100.36 | 63.643         | 0.536                         |
| 31-40 years                                    | 52 | 115.62 | 56.166         |                               |
| > 40 years                                     | 30 | 109.93 | 56.251         |                               |
| CD4 count at 12 months of treatment based on age |    |      |                |                               |
| 18-30 years                                    | 28 | 297.14 | 248.405        | 0.584                         |
| 31-40 years                                    | 52 | 322.44 | 147.725        |                               |
| > 40 years                                     | 30 | 282.13 | 133.246        |                               |

Table 4: Wilcoxon signed ranks test is used to highlight the difference in viral load between the two time points under this study

| Before HAART | At 12 months of HAART | Wilcoxon Signed Ranks Test |
|--------------|------------------------|---------------------------|
| Number of Patients | 110 | 110 | 0.000 |
| Median (Logs) | 23400(4.3) | 20(1.3) | |
| Minimum (Logs) | 461(2.6) | 20(1.3) | |
| Maximum (Logs) | 2950000(6.4) | 695000(5.8) | |
Table 5: Viral load level based on sex and age. However, there was no significant difference detected between the groups

| Variables                                         | N     | Mean Rank | Mann-Whitney Test/ Kruskal-Wallis Test |
|---------------------------------------------------|-------|-----------|----------------------------------------|
| Viral load before HAART initiation based on sex    |       |           |                                        |
| Male                                              | 63    | 59.94     | 0.090                                  |
| Female                                            | 47    | 49.54     |                                        |
| Viral load at 12 months of treatment based on sex  |       |           |                                        |
| Male                                              | 63    | 55.25     | 0.766                                  |
| Female                                            | 47    | 55.84     |                                        |
| Viral load before HAART initiation based on age    |       |           |                                        |
| 18-30 years                                       | 28    | 56.02     | 0.918                                  |
| 31-40 years                                       | 52    | 54.25     |                                        |
| > 40 years                                        | 30    | 57.18     |                                        |
| Viral load at 12 months of treatment based on age  |       |           |                                        |
| 18-30 years                                       | 28    | 59.38     | 0.063                                  |
| 31-40 years                                       | 52    | 53.5      |                                        |
| > 40 years                                        | 30    | 55.35     |                                        |

Table 6: CD4+ cell recovery and level of viremia following HAART with regard to a target of >200 cells/μl

| CD4 cells after Treatment | Frequency | Percentage |
|---------------------------|-----------|------------|
| CD4 count ≤ 200 cells/μl  | 29        | 26.4       |
| CD4 count > 200 cells/μl  | 81        | 73.6       |
| Viremia decrease to up to 20 RNA/ml | 106 | 96.4 |
| Increase in viremia       | 4         | 3.6        |
| Variables | Total, N | CD4 count ≤ 200 cells/μl, n(%) | CD4 count > 200 cells/μl, n(%) | OR (95% CI) | Chi square +p value |
|-----------|---------|--------------------------------|--------------------------------|-------------|-------------------|
| Sex       |         |                                |                                |             |                   |
| Male      | 63      | 17(27.0%)                      | 46(73.0%)                      | 1.10(0.46-2.55) | 0.864             |
| Female    | 47      | 12(25.5%)                      | 35(74.5%)                      | 1.00        |                   |
| Age in years |        |                                |                                |             |                   |
| 18-30     | 28      | 13(46.4%)                      | 15(53.6%)                      | 4.33(1.29-14.59) | **0.018**         |
| 31-40     | 52      | 11(21.2%)                      | 41(78.8%)                      | 1.34(0.42-4.32) | 0.622             |
| > 40      | 30      | 5(16.7%)                       | 25(83.3%)                      | 1.00        |                   |

OR= Odds Ratio; CI= Confidence Interval; +Significant p value